| Project/Area Number |
24591151
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Yamagata University |
|---|
Principal Investigator |
Kurotani Reiko 山形大学, 理工学研究科, 准教授 (00453043)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ABE Hiroyuki 山形大学, 大学院理工学研究科, 教授 (10375199)
SHIBATA Yoko 山形大学, 医学部, 講師 (60333978)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
KUMAKI Nobue 東海大学, 医学部, 講師 (90366021)
|
|---|
| Project Period (FY) |
2012-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | SCGB3A2 / 肺線維症 / ＳＣＧＢ３Ａ２ / ブレオマイシン / トレッドミル / アポトーシス |
|---|
| Outline of Final Research Achievements |
Pulmonary fibrosis is induced to develop by the side effects of bleomycin (BLM), which is used as a radiation and anti-cancer agent in the treatment of cancer. Since the pathogenesis of pulmonary fibrosis is not sufficient, and definitive therapeutic agent is not present, elucidation of the onset mechanism of pulmonary fibrosis and the development of the new therapeutic drug become the urgent business. New bioactive substance Secretoglobin (SCGB)3A2 has roles of the anti-inflammatory effect, pulmonary fibrosis improvement effect, as well as promotes growth, branching, and maturation in the lung development. SCGB3A2 having such a multi-function was expected to be physiologically active substances with the potential as an effective treatment of pulmonary fibrosis. This study demonstrated the possible therapeutic use of SCGB3A2 in treatment of lung fibrosis.
|
